Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Income from Continuing Operations of 150049000.0 for Q1 2026, up 27.06% year-over-year from 118095000.0 in Q1 2025, and up 205.97% quarter-over-quarter from 141591000.0 in Q4 2025.
Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Income from Continuing Operations for 17 consecutive years, with 150049000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 27.06% year-over-year to 150049000.0; the TTM figure through Mar 2026 stood at 348876000.0 (down 28.12% YoY), while the FY2025 annual figure was 316889000.0, down 28.64% from the prior year.
- Income from Continuing Operations grew to 150049000.0 in Q1 2026 per HALO's latest filing, from 141591000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 175258000.0 in Q3 2025 and bottomed at 141591000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 82046176.47 across 5 years, with a median of 81837000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 229.53% — and 2025, when it plunged 203.34%.
- Halozyme Therapeutics' Income from Continuing Operations stood at 57702000.0 in 2022, then soared by 47.98% to 85388000.0 in 2023, then soared by 60.46% to 137012000.0 in 2024, then slumped by 203.34% to 141591000.0 in 2025, then surged by 205.97% to 150049000.0 in 2026.
- Business Quant data shows HALO's Income from Continuing Operations at 150049000.0 in Q1 2026, 141591000.0 in Q4 2025, and 175258000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 229.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 229.90 Mn |
| Mar 31, 2026 | 150.05 Mn |
| Dec 31, 2025 | -141.59 Mn |
| Sep 30, 2025 | 175.26 Mn |
| Jun 30, 2025 | 165.16 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 137.01 Mn |
| Sep 30, 2024 | 137.01 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 76.82 Mn |
| Dec 31, 2023 | 85.39 Mn |
| Sep 30, 2023 | 81.84 Mn |
| Jun 30, 2023 | 74.75 Mn |
| Mar 31, 2023 | 39.62 Mn |
| Dec 31, 2022 | 57.70 Mn |
| Sep 30, 2022 | 61.63 Mn |
| Jun 30, 2022 | 22.69 Mn |
| Mar 31, 2022 | 60.11 Mn |
| Dec 31, 2021 | 66.77 Mn |
| Sep 30, 2021 | 216.59 Mn |